A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation
NCT00285415
Terminated
The purpose of this study is to determine the effectiveness of the combination of the two drugs, docetaxel (Taxotere®) and carboplatin (Paraplatin®) followed by radiation directed at the tumor in treating your endometrial cancer.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
02/03/2021
Locations: Gynecologic Oncology Research & Development, LLC, Greenville, South Carolina +1 locations
Conditions: Advanced Endometrial Adenocarcinoma, Stage III A, B, C
Register for Updates
Neoadjuvant Therapy for Ovarian Cancer
NCT01146795
Completed
This study is to determine the feasibility of administering neoadjuvant carboplatin, paclitaxel, and bevacizumab without excessive dose modification or cycle delay in patients with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. This study will also investigate the rate of optimal cytoreduction, response rate and progression free and overall survival, and to assess the quality of life for patients with epithelial ovarian cancer, primary peritoneal cancer or fallopi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/20/2021
Locations: Columbia University Medical Center, New York, New York +2 locations
Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
NCT02032277
Completed
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/15/2021
Locations: Scottsdale Healthcare /ID# 120473, Scottsdale, Arizona +157 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery
NCT01183559
Completed
The purpose of the study is to determine the most tolerable and safe dose of ZD6474 (Zactima, Vandetanib) when given with standard chemotherapy, radiation therapy and surgery in patients with cancer of the esophagus
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2021
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach
Register for Updates
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
NCT00662597
Terminated
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: University of South Alabama/Mitchell Cancer Institute, Mobile, Alabama +248 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
NCT01289353
Completed
The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy and radiotherapy in breast cancer patients after breast surgery.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: NYU Cancer Center, New York, New York
Conditions: Breast Cancer
Register for Updates
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
NCT01169636
Completed
Objectives: Primary objective: * Phase-I: To determine the maximal tolerated dose (MTD) of panobinostat (LBH589) + Ifosfamide + Mesna, Carboplatin and Etoposide (ICE) combination * Randomized Phase-II: To estimate the complete response (CR) rate in patients with relapsed and refractory classical Hodgkins Lymphoma (HL) receiving ICE versus PANOBINOSTAT plus ICE therapy Secondary Objectives: * To assess the safety and tolerability of the novel combination of PANOBINOSTAT (LBH589) plus ICE vers... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
12/10/2020
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Hodgkin's Lymphoma
Register for Updates
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
NCT01934361
Completed
This is a multi-center, phase Ib/ II study (two parts) with patients that had recurrent glioblastoma multiforme. The first part (phase Ib) was to investigate the maximum tolerated dose/Recommended phase ll dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin or buparlisib once daily in combination with every-six-week lomustine (CCNU) using a Bayesian model. Once MTD/ RP2D is established in either of the 2 arms, the corresponding phase II portion of the study... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2020
Locations: Barrow Neurological Insitute St. Joseph's Hospital, Phoenix, Arizona +13 locations
Conditions: Recurrent Glioblastoma Multiforme
Register for Updates
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer
NCT01268059
Terminated
The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
12/01/2020
Locations: Research Site, Fountain Valley, California +28 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
NCT02106546
Completed
The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/13/2020
Locations: Northeast Arkansas Clinical Ch /ID# 128071, Jonesboro, Arkansas +224 locations
Conditions: Squamous Non-Small Cell Lung Cancer
Register for Updates
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel
NCT01051570
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving carboplatin together with everolimus and prednisone may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving carboplatin togeth... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
11/06/2020
Locations: Northshore University Health System, Evanston, Illinois +3 locations
Conditions: Prostate Cancer
Register for Updates
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
NCT01412229
Completed
This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2020
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina +2 locations
Conditions: Head and Neck Cancer
Register for Updates